Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:268796.
doi: 10.1155/2015/268796. Epub 2015 Jun 8.

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab

Andrea Perdicchi  1 , Giacomo Peluso  1 , Daniela Iacovello  1 , Marco Balestrieri  1 , Martina Delle Fave  1 , Solmaz Abdolrahimzadeh  2 , Gian Luca Scuderi  1 , Vito Fenicia  1 , Santi Maria Recupero  1
Affiliations

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab

Andrea Perdicchi et al. Biomed Res Int. 2015.

Abstract

Purpose. To detect the effects of intravitreal ranibizumab injections on GCC in patients with wet AMD. Methods. 32 wet AMD eyes were selected and submitted at three ranibizumab injections. RTVue-OCT GCC and MM5 protocol were performed before treatment and twenty days after each injection. Results. At baseline mean GCC thickness was 93.9 ± 18.5 μm. Twenty days after each intravitreal injection it was, respectively, 85.8 ± 10.1, 86.5 ± 9.3, and 91.1 ± 11.5 μm, without statistical significance. A significant improvement in visual acuity (P = 0.031) and a reduction of mean foveal (P = 0.001) and macular thickness (P = 0.001) were observed. Conclusion. The clinical results confirm therapeutic efficacy of intravitreal injections of ranibizumab in wet AMD. A contemporary not statistically significant reduction of GCC thickness suggests that the loading phase of ranibizumab does not have any toxic effects on ganglion cell complex.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Thickness map, significance map, and average value of GCC.
Figure 2
Figure 2
Example of macular map, divided into 9 areas.
See this image and copyright information in PMC

References

    1. Klaver C. C. W., Assink J. J. M., Van Leeuwen R., et al. Incidence and progression rates of age-related maculopathy: the rotterdam study. Investigative Ophthalmology and Visual Science. 2001;42(10):2237–2241. - PubMed
    1. Oh H., Takagi H., Takagi C., et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Investigative Ophthalmology and Visual Science. 1999;40(9):1891–1898. - PubMed
    1. Steinbrook R. The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration. The New England Journal of Medicine. 2006;355(14):1409–1412. doi: 10.1056/NEJMp068185. - DOI - PubMed
    1. Fenicia V., Abdolrahimzadeh S., Mannino G., Verrilli S., Balestrieri M., Recupero S. M. Intravitrealbevacizumab in the successful management of choroidal metastases secondary to lung and breast cancer unresponsive to systemictherapy: a case series. Eye. 2014 doi: 10.1038/eye.2014.96. - DOI - PMC - PubMed
    1. Fenicia V., Balestrieri M., Perdicchi A., Maraone G., Recupero S. M. Intravitreal injection of dexamethasone implant in serous macular detachment associated with Waldenström's disease. Case Reports in Ophthalmology. 2013;4(2):64–69. doi: 10.1159/000354066. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources